Slide 1: Fourth Quarter Fiscal 2026 Results
Fourth Quarter Fiscal 2026 Results May 7, 2026 © 2026 Haemonetics Corporation
Slide 2: Q4 Fiscal 2026 Conference Call Detail
Q4 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on Conference call speakers: May 7, 2026, and can be accessed via live webcast: Link or teleconference: Link. Chris Simon The earnings release, accompanying slides and a President & CEO replay of the conference cal
Slide 3: Important Information
Important Information Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historic
Slide 4: Q4 Fiscal 2026 Highlights
Q4 Fiscal 2026 Highlights Delivering revenue growth despite last year’s portfolio transitions • 4.8% reported revenue growth; 4.5% organic1 revenue growth; 8.6% organic ex-CSL2 revenue growth. • Gross margin down 120bps Y/Y to 57.2%; Adjusted gross margin down 50bps Y/Y to 59.7%. • Operating margin
Slide 5: Delivering on Our Transformational Growth Commitments
Delivering on Our Transformational Growth Commitments1 LRP Goals FY’22 - FY’26 Organic Revenue High Single Digit 10% CAGR; Growth (FY’22 – FY’26 CAGR) 13% CAGR ex-CSL Adjusted Operating High Twenties 25.4% Margin (in FY’26) + ~660 bps expansion Adjusted EPS Mid Teens 18% Growth (FY’22 – FY’26 CAGR)
Slide 6: Q4 Fiscal 2026 Revenue by Business Unit
Q4 Fiscal 2026 Revenue by Business Unit Revenue (in millions) Organic Reported Organic Q4 2026 Q4 2025 growth, $346 growth growth4 $331 (in millions) ex-CSL Plasma $130.3 $126.7 2.8% 1.8% 12.7% Apheresis $56.4 $54.3 3.9% 5.5% 5.5% Whole Blood – $1.7 (100.0%) – – Blood Center $56.4 $56.0 0.7% 5.5% 5.
Slide 7: Q4 Fiscal 2026 Financial Review
Q4 Fiscal 2026 Financial Review GAAP Results1: Non-GAAP Results: Q4 2026 Q4 2025 Y/Y Q4 2026 Q4 2025 Y/Y Gross Margin % 57.2% 58.4% -120bps Adjusted Gross Margin % 59.7% 60.2% -50bps Operating Margin % (6.6%) 21.6% -2,820bps Adjusted Operating Margin % 24.4% 24.9% -50bps Net (Loss) Income Margin % (
Slide 8: Q4 Fiscal 2026 Segment Performance
Q4 Fiscal 2026 Segment Performance Plasma Q4 2026 Q4 2025 Y/Y Revenue $130.3M Performance$126.7M Highlights: 2.8% reported; 12.7% organic ex–CSL Adjusted Operating Margin %1 33.5% 40.0% -650bps Blood Center Q4 2026 Q4 2025 Y/Y 0.7% reported; Revenue $56.4M $56.0M 5.5% organic Adjusted Operating Marg
Slide 9: Balance Sheet and Cash Flow Metrics
Balance Sheet and Cash Flow Metrics Cash from operations (dollars in millions) 4 ($ millions) 3/28/26 3/29/25 FCF CapEx and Other $293 Cash & cash equivalents $245 $307 $83 Working capital $552 $357 $182 Total debt $1,225 $1,225 $37 $117 Net debt1 $980 $918 $22 $210 $71 $145 Available credit2 $749 $
Slide 10: Full Year Fiscal 2027 Guidance
Full Year Fiscal 2027 Guidance Guidance as of May 7, 2026 Reported Revenue 4 – 7% Organic Revenue Guidance Includes: • Plasma: ~ MSD Growth 53rd Week Impact (~2%) • Hospital: ~ MSD Growth • Blood Center: ~ MSD Decline Currency Impact 0 – 1% Organic Revenue1 3 – 6% Adjusted Operating Margin 50 – 100
Slide 11: Appendices
Appendices © 2026 Haemonetics Corporation
Slide 12: Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates
Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates 2025 CSL US Organic Currency Acquisitions & Organic ($ millions) Q4 2026 Q4 2025 Reported growth Disposable growth, impact Divestitures1 growth1 Revenue2 ex-CSL Plasma $130.3 $126.7 2.8% 1.0% – 1.8% (10.9%) 12.7% A
Slide 13: Appendix B: Reconciliation of GAAP to Organic Revenue and Adjusted EPS CAGR
Appendix B: Reconciliation of GAAP to Organic Revenue and Adjusted Earnings Per Share Compounded Annual Growth Rate (CAGR) (Revenue $ in millions) FY 2026 FY 2022 Actual Actual CAGR Reported Revenue $1,334.0 $993.2 7.7% Acquisitions and Divestitures Impact ($47.7) ($76.4) Currency Impact ($16.9) ($4
Slide 14: Appendix C: Reconciliation of GAAP to Non-GAAP Q4 Fiscal 2026 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q4 Fiscal 2026 Financial Results Interest and (Loss) (Benefit) Operating Operating other Net (loss) Earnings Gross profit provision for ($ millions) expenses (loss) income (expense) income per diluted income taxes income share1,2 Reported $198.2 $221.2
Slide 15: Appendix C: Reconciliation of GAAP to Non-GAAP Q4 Fiscal 2025 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q4 Fiscal 2025 Financial Results Earnings Interest and Provision Operating Operating Net income (loss) per Gross profit other (benefit) for ($ millions) expenses income (loss) (loss) diluted expense income taxes share Reported $193.1 $121.7 $71.3 ($0.6)
Slide 16: Appendix C: Reconciliation of GAAP to Non-GAAP Fiscal 2026 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Fiscal 2026 Financial Results Interest and Earnings Provision Operating Operating other Net income (loss) per Gross profit (benefit) for ($ millions) expenses income (loss) (expense) (loss) diluted income taxes income share Reported $787.6 $630.9 $156.7
Slide 17: Appendix C: Reconciliation of GAAP to Non-GAAP Fiscal 2025 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Fiscal 2025 Financial Results Interest and Provision Earnings Operating Operating Net income (loss) per Gross profit other (benefit) for ($ millions) expenses income (loss) (loss) diluted expense income taxes share Reported $749.0 $527.1 $221.8 ($9.7) $
Slide 18: Appendix D: Reconciliation of Cash Flows
Appendix D: Reconciliation of Cash Flows ($ millions) Q4 2026 Q4 2025 FY 2026 YTD FY 2025 YTD Free Cash Flow Reconciliation Cash provided by operating activities $70.9 $116.6 $293.2 $181.7 Capital expenditures ($17.7) ($15.6) ($32.8) ($39.3) Additions to Haemonetics equipment ($9.3) ($8.5) ($51.9) (
Slide 19: Appendix E: Reconciliation of Segment Operating Income
Appendix E: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2) Q4 2026 Q4 2025 Net revenues: Plasma $130.3 $126.7 Blood Center $56.4 $56.0 Hospital $159.6 $147.9 Total net revenues $346.4 $330.6 Significant segment expenses and operating performance: Plasma Cost of g
Slide 20: Appendix E: Reconciliation of Segment Operating Income
Appendix E: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2) Q4 2026 Q4 2025 Corporate and unallocated expenses Amortization of acquired assets ($10.5) ($13.9) Integration and transaction costs ($9.4) ($7.3) Restructuring and restructuring related costs ($0.2) ($2.